Delivery Order 36F79721D0068-36C26025F0230
Award Date
4/24/25
Potential Completion Date
9/30/25
Potential Value
$102K
Federal Agency
Veterans Integrated Service Network 20
Awardee
Urogen Pharma Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Dublin, OH 43017, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Department of Veterans Affairs (VA) to UroGen Pharma Inc., a for-profit pharmaceutical company, for the supply of JELMYTO kits. The contract has a ceiling value of $102,264.12 and is valid through September 30, 2025. The contract was issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and is structured as a firm fixed-price delivery order. No set-aside was used. UroGen Pharma has held multiple indefinite delivery vehicle...
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 21 awarded a $194,860.32 delivery order to Urogen Pharma Inc. under the Pharmaceuticals and Drugs Federal Supply Schedule contract. The firm fixed price order is for the delivery of JELMYTO mitomycin and has an anticipated completion date of August 9, 2023. Placement on the Pharmaceuticals and Drugs FSS vehicle establishes pre-negotiated pricing terms for ordering agencies like the VA to...
This federal contract award is for the delivery of the pharmaceutical drug Jynarque (tolvaptan) to the U.S. Department of Veterans Affairs (VA) by Otsuka America Pharmaceutical Inc., a for-profit pharmaceutical manufacturer. The contract has an award value of $12,559.90 and a period of performance through August 6, 2024. Jynarque is used to treat autosomal dominant polycystic kidney disease and hyponatremia. The contract was issued under Otsuka's Federal Supply Schedule (FSS) contract with the...
This federal contract award is for the delivery of the drug Jynarque (tolvaptan) to the Department of Veterans Affairs (VA) Veterans Health Administration (VHA) facilities and VA Veterans Integrated Service Networks. The contract was awarded to the prime contractor Otsuka America Pharmaceutical Inc., a for-profit manufacturer and supplier of pharmaceuticals. The contract has a potential value of $146,493.98 and was awarded on a firm-fixed price basis with no set-aside designation. It is...
This federal contract award is for the delivery of the drug Jynarque (tolvaptan) to the U.S. Department of Veterans Affairs (VA). The contract was awarded to Otsuka America Pharmaceutical Inc., a for-profit pharmaceutical manufacturer and supplier. The contract is a Delivery Order under Otsuka's existing Federal Supply Schedule (FSS) contract with the VA, which has a ceiling value of $396 million and allows for the procurement of a range of Otsuka's pharmaceutical products to support...
This is a firm-fixed price delivery order contract awarded by the Department of Veterans Affairs (VA) to Otsuka America Pharmaceutical Inc., a for-profit pharmaceutical manufacturer and supplier. The contract, valued at $730,030.82, is for the delivery of the drug Jynarque (tolvaptan) to VA medical facilities across the country. Jynarque is used to treat autosomal dominant polycystic kidney disease and hyponatremia. The contract is issued under the VA's Pharmaceuticals and Drugs Federal Supply...
This federal contract award was made by the Department of Veterans Affairs (VA) to Otsuka America Pharmaceutical Inc., a for-profit pharmaceutical manufacturer and supplier. The contract is for the delivery of the medication Jynarque (tolvaptan), which is used to treat autosomal dominant polycystic kidney disease and hyponatremia. The contract is a Blanket Purchase Agreement (BPA) with a ceiling value of $113,303.91 and a period of performance from October 2020 to October 2021. It was awarded...
This federal contract award to Otsuka America Pharmaceutical Inc., a for-profit pharmaceutical manufacturer, is for the delivery of the drug Jynarque (tolvaptan) to the U.S. Department of Veterans Affairs (VA). The contract, valued at $12,580.72, is a delivery order issued under two larger Indefinite Delivery Vehicles (IDVs) held by Otsuka with the VA: a $15 million Blanket Purchase Agreement (BPA) and a $396 million Federal Supply Schedule (FSS) contract, both awarded in March 2020 and set to...
This federal contract award is a delivery order placed by the Department of Veterans Affairs (VA) San Diego Pharmacy Service with Otsuka America Pharmaceutical Inc., a for-profit pharmaceutical manufacturer. The $180,972.27 contract is for the sole-source procurement of Jynarque (tolvaptan), a medication used to treat autosomal dominant polycystic kidney disease and hyponatremia. The contract is issued under Otsuka's $396 million Federal Supply Schedule (FSS) contract with the VA for...
This federal contract award to Otsuka America Pharmaceutical Inc. is for the delivery of the drug Jynarque (tolvaptan) to the U.S. Department of Veterans Affairs (VA). The $94,669.12 firm-fixed-price delivery order, which has an ultimate completion date of December 19, 2023, was awarded on December 20, 2022 under the VA's Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract. Otsuka, a for-profit pharmaceutical manufacturer, is supplying various dosages of Jynarque to VA medical...